SynthesisVirology journal2025
Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data.
Synthesis in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Infection-associated acute kidney injury in resource-limited settings.Nature reviews. Nephrology · 2026Review
- Barriers in operating proactive source reduction informed by an early warning system for dengue prevention: A qualitative study from end-user perspectives in Vietnam.PLoS neglected tropical diseases · 2026Article
- Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDengue is one of the fastest spreading arboviral infection with no specific antiviral treatment, making vaccination a significant preventive approach. Several dengue vaccines have been developed, but their efficacy, safety, and serotype-specific protection remain areas of concern. Over the past five years, new clinical data have emerged, influencing vaccine recommendations and deployment strategies. This systematic review analyses recent dengue vaccine data, assessing their effectiveness, and safety profiles.
methodsData was taken from three different databases i.e. PubMed, Cochrane and google scholar from last five years (2020-2025) by using the specific search terms. Filters were applied to extract the studies relevant to our analysis. Data was analysed and forest plots were made for proper understanding of vaccine efficacy and safety data of vaccines.
results14 studies are included in the study and our systematic review study on dengue vaccines revealed TAK-003 and TV005 with highest protection rates in their respective settings. Safety profiles varied: TAK-003 and CYD-TDV reduced serious events, whereas TV005 was associated with heightened reactogenicity.
conclusionThis review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.